Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Stephen O'Brien.

Newcastle AuthorsTitleYearFull text
Dr Matthew Barter
Kat Cheung
Julia Falk
Dr Andreas Panagiotopoulos
Professor Stephen O'Brien
et al.
Dynamic chromatin accessibility landscape changes following interleukin-1 stimulation2021
Dr Ed Schwalbe
Dr Peter Carey
Professor Stephen O'Brien
Professor Anthony Moorman
Emilio Barretta
et al.
Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting — the Blantyre experience2020
Dr Wendy Osborne
Professor Stephen O'Brien
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial2019
Professor Stephen O'Brien
Trial re-investment to build better research for better impact2019
Professor Stephen O'Brien
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial2017
Professor Stephen O'Brien
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.2017
Dr Ed Schwalbe
Dr Kevin Windebank
Professor Stephen O'Brien
Dr Peter Carey
Professor Simon Bailey
et al.
The use of anthracyclines in the treatment of endemic Burkitt lymphoma2017
Professor Stephen O'Brien
De-escalation of tyrosine kinase inhibitor therapy is safe in chronic myeloid leukaemia in durable molecular response (>= mr3 for >= 12 months): initial results in the British DESTINY study2016
Corrine Hedgley
Professor Stephen O'Brien
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase2015
Leanne Cork
Corinne Hedgley
Dr Wendy Osborne
Gemma Gills
Ruth Bescoby
et al.
Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia2015
Leanne Cork
Corrine Hedgley
Professor Stephen O'Brien
Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences2015
Dr Wendy Osborne
Professor Stephen O'Brien
Corinne Hedgley
Ruth Bescoby
SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia-2 year follow up2015
Dr Samuel Moses
Professor Stephen O'Brien
Dr Tobias Menne
Dr Jonathan Wallis
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia2014
Professor Stephen O'Brien
Corinne Hedgley
Lynn Alaily
Dr Wendy Osborne
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML2014
Professor Stephen O'Brien
Corinne Hedgley
Dr Wendy Osborne
SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML2014
Professor Stephen O'Brien
Diagnosis and treatment of chronic myeloid leukemia2013
Professor Stephen O'Brien
Corinne Hedgley
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia2012
Dr Samuel Moses
Professor Stephen O'Brien
Dr Tobias Menne
Dr Jonathan Wallis
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia2012
Professor Stephen O'Brien
Corinne Hedgley
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib2012
Professor Stephen O'Brien
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib2010
Professor Stephen O'Brien
Professor Julie Irving
Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype2010
Professor Stephen O'Brien
KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib2010
Dr Michelle Muller
Professor Stephen O'Brien
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)2010
Professor Stephen O'Brien
A Gene Expression Signature of CD34+Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance2009
Professor Stephen O'Brien
Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase2009
Professor Stephen O'Brien
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial2009
Professor Stephen O'Brien
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib2009
Professor Stephen O'Brien
Seven year follow-up of the International Randomized Study of Interferon Versus STI571 (IRIS) demonstrates durable efficacy and long-term safety of imatinib in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP)2009
Professor Stephen O'Brien
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia2009
Professor Stephen O'Brien
Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy2009
Professor Stephen O'Brien
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment2008
Professor Stephen O'Brien
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation2008
Professor Stephen O'Brien
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study2008
Jean Norden
Professor Stephen O'Brien
Improved single nucleotide polymorphisms detection using conjugated polymer/surfactant system and peptide nucleic acid2008
Professor Stephen O'Brien
International Randomized Study of Interferon Versus ST1571 (IRIS) 7-year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM)2008
Professor Stephen O'Brien
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia2008
Dr Michelle Muller
Professor Stephen O'Brien
Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)2008
Dr Feng Lin
Professor Stephen O'Brien
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR2007
Professor Stephen O'Brien
Cytogenetic response and discontinuations from IRIS study with long-term imatinib therapy in newly diagnosed Ph+ chronic myelogenous leukemia2007
Professor Stephen O'Brien
Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)2007
Professor Stephen O'Brien
Imatinib plasma concentration and sokal risk score are independently prognostic for complete cytogenetic response (CCyR) in patients with chronic phase chronic myeloid leukemia (CML-CP)2007
Professor Stephen O'Brien
IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), treated with imatinib2007
Professor Stephen O'Brien
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance2007
Professor Stephen O'Brien
Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance2007
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Professor Herbie Newell
Professor Stephen O'Brien
et al.
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia2007
Dr Udo Holtick
Dr Scott Marshall
Professor Stephen O'Brien
Professor Matthew Collin
Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia2007
Professor Stephen O'Brien
Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy2007
Professor Stephen O'Brien
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP)2006
Professor Stephen O'Brien
A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)2006
Professor Stephen O'Brien
Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - An analysis of IRIS study data2006
Professor Stephen O'Brien
Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the international randomized study of interferon vs STI571 (IRIS)2006
Professor Stephen O'Brien
Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate2006
Professor Stephen O'Brien
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia2006
Professor Stephen O'Brien
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study2006
Professor Stephen O'Brien
Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS trial2006
Professor Stephen O'Brien
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials2006
Dr Lucy Crossman
Professor Stephen O'Brien
Dr Peter Middleton
A gene polymorphism within the kinase domain of BCR-ABL and its effects on sensitivity to tyrosine kinase inhibitors2005
Dr Lucy Crossman
Professor Stephen O'Brien
Dr Peter Middleton
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib2005
Jill Crossman
Professor Stephen O'Brien
Gene expression profiling of CML CD34+ cells prior to imatinib therapy reveals differences between patients with and without subsequent complete cytogenetic response2005
Professor Stephen O'Brien
Chronic myelogenous leukemia and myeloproliferative disease2004
Dr Lucy Crossman
Professor Stephen O'Brien
Clinical results with imatinib in chronic myeloid leukaemia2004
Dr Lucy Crossman
Professor Stephen O'Brien
Imatinib therapy for chronic myeloid leukemia2004
Professor Julie Irving
Professor Stephen O'Brien
Dr Anne Lennard
Lynne Minto
Dr Feng Lin
et al.
Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib2004
Dr Feng Lin
Professor Stephen O'Brien
An international study to standardize the detection of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR2003
Professor Stephen O'Brien
Designer drugs for fusion genes: imatinib and chronic myeloid leukaemia2003
Professor Julie Irving
Professor Stephen O'Brien
Dr Anne Lennard
Dr Feng Lin
Emeritus Professor Andy Hall
et al.
The use of denaturing high-performance liquid chromatography (DHPLC) for the detection of mutations in the bcr-abl oncogene in patients resistant to imatinib2003
Professor Stephen O'Brien
Continuous oral lonafarnib (Sarasar (TM)) for the treatment of patients with advanced hematologic malignancies: A phase II study2002
Dr John Byrne
Professor Stephen O'Brien
Dr Anne Lennard
Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.2002
Professor Stephen O'Brien
Phase I study of continuous oral administration of lonafarnib (Sarasar (TM)) in patients with advanced hematologic malignancies2002
Professor Stephen O'Brien
Use of imatinib mesylate in patients with CML in chronic phase resistant to interferon-alfa: Factors defined at start of therapy that predict disease progression and survival2002
Professor Stephen O'Brien
A pharmacokinetic interaction of Glivec (R) and Simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia2001
Gavin Cuthbert
Julie Freeman-Edward
Dr Anne Lennard
Professor Stephen O'Brien
Dr Nicholas Bown
et al.
Der(9) deletions and response to STI571(Glivec (R)) treatment in chronic phase CML patients.2001
Dr Annette Neylon
Professor Stephen O'Brien
Dr Peter Middleton
IL-4 gene polymorphism and outcome following sibling allogeneic bone marrow transplant2001
Professor Stephen O'Brien
Imatinib for chronic myeloid leukaemia: a NICE mess2001
Professor Stephen O'Brien
Imatinib for chronic myeloid leukaemia: A NICE mess [multiple letters]2001
Dr Annette Neylon
Professor Stephen O'Brien
Improving the management of chronic myeloid leukaemia2001
Professor Stephen O'Brien
Susan Tremble
PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia2001
Dr Feng Lin
Professor Stephen O'Brien
Dr Anne Lennard
Response of chronic phase CML patients to STI571 therapy assessd by quantitative real time PCR2001
Dr Annette Neylon
Professor Stephen O'Brien
Dr Peter Middleton
The correlation of cytokine gene polymorphisms with outcome in chronic phase CML patients undergoing allogeneic BMT2001
Denise Howel
Professor Stephen O'Brien
Dr David Chinn
Professor Peter Blain
Upper aerodigestive tract cancers in former employees at an iron and steel works2001